The biggest new drugs in a generation GLP-1 receptor agonists like semaglutide and the dual GIP/GLP-1 agonist tirzepatide mimic naturally occurring hormones that regulate blood sugar, appetite, and digestion
Different eligibility, different funding routes, different review requirements
Lancet 398 , 583598 (2021) D
Notably, exenatide immediate-release (Byetta) and lixisenatide (Adlyxin, and in Soliqua) do not carry this boxed warning or contraindication
Mild water retention and peripheral edema, particularly during weeks one to four Transient flushing, warmth, or dizziness immediately post-injection Injection site reactions: redness, minor swelling Dose-dependent effects (above saturation dose of approximately 1 mcg/kg): Elevated cortisol via ACTH stimulation